• LeonaBio outlined plans to spotlight lasofoxifene at DAVA Oncology’s breast cancer summit on Aug. 18-22, 2026.
• No new trial results were disclosed; Phase 3 ELAINE-3 enrollment remains on track to finish in 4Q 2026.
• Topline ELAINE-3 data are expected in 2H 2027, setting up a major catalyst for the metastatic breast cancer program.
• The study tests lasofoxifene with abemaciclib in ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer.
• Management positioned the regimen as a potential new treatment option if the pivotal trial delivers supportive efficacy and safety outcomes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LeonaBio Inc. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.